InspireMD (STU:II2) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 11, 2026)


STU:II2 InspireMD Inc STU:II2
41 GF Score
Price €0.63
GF Value €1.50
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is InspireMD 5-Year Yield-on-Cost %?

InspireMD STU:II2 +2.46% 41 5-Year Yield-on-Cost % is 0.00 as of Jul. 11, 2026. GuruFocus rates STU:II2 with a GF Score™ of 41/100 and a GF Value™ of €1.50 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 327 Medical Devices & Instruments companies, InspireMD ranks worse than 305810.09% on this metric.

InspireMD's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for InspireMD's 5-Year Yield-on-Cost % or its related term are showing as below:



STU:II2's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.34
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

InspireMD  (STU:II2) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


InspireMD 5-Year Yield-on-Cost % Related Terms


STU:II2 vs TELA, BDMD, PAVM: 5-Year Yield-on-Cost % Comparison

For the Medical Devices subindustry, InspireMD's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InspireMD 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, InspireMD's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where InspireMD's 5-Year Yield-on-Cost % falls into.


STU:II2
41GF Score
InspireMD Inc STU:II2
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InspireMD 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of InspireMD is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
InspireMD (STU:II2) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 11, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on InspireMD and its competitors. According to the industry distribution chart, InspireMD ranks #999999 out of 327 companies in the Medical Devices & Instruments industry.
Is InspireMD's 5-Year Yield-on-Cost % too high?
InspireMD's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, InspireMD ranks #999999 out of 327 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, InspireMD has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InspireMD's 5-Year Yield-on-Cost % compare to TELA and BDMD?
According to the Medical Devices & Instruments industry distribution chart, InspireMD ranks #999999 out of 327 companies for 5-Year Yield-on-Cost %. This places InspireMD in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.34, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on InspireMD and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InspireMD's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InspireMD stock overvalued right now?
Based on GuruFocus' analysis, InspireMD (STU:II2) is currently considered Possible Value Trap. The stock's GF Value™ is €1.50, compared to a current price of €0.63 — trading 58.3% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. InspireMD's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For InspireMD (STU:II2), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InspireMD (STU:II2) Overvalued in 2026?

Based on GuruFocus' analysis, InspireMD stock appears to be undervalued. The current stock price of €0.63 is trading 58.3% below its estimated GF Value™ of €1.50. GuruFocus considers InspireMD to be Possible Value Trap.

Key valuation signals for STU:II2:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: €1.50 vs. price of €0.63 (58.3% below fair value)
  • GF Score™: 41/100 with 3 warning signs

No single metric tells the full story. See the STU:II2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


InspireMD Business Description

Other Exchanges NSPR:USA
Address 6303 Waterford District Drive, Suite 215, Miami, FL, USA, 33126
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
41GF Score

Get the complete analysis for STU:II2

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.63
Price
€1.50
GF Value